Novo Nordisk Quick Ratio 2010-2022 | NVO

Historical quick ratio values for Novo Nordisk (NVO) over the last 10 years.
Novo Nordisk Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-06-30 $11.62B $15.68B 0.74
2022-03-31 $9.99B $14.42B 0.69
2021-12-31 $10.50B $15.83B 0.66
2021-09-30 $11.47B $14.01B 0.82
2021-06-30 $9.45B $11.80B 0.80
2021-03-31 $6.93B $11.73B 0.59
2020-12-31 $7.24B $10.77B 0.67
2020-09-30 $8.72B $11.14B 0.78
2020-06-30 $8.24B $9.94B 0.83
2020-03-31 $6.78B $9.33B 0.73
2019-12-31 $6.72B $8.84B 0.76
2019-09-30 $6.84B $9.40B 0.73
2019-06-30 $6.26B $8.52B 0.74
2019-03-31 $5.46B $8.33B 0.66
2018-12-31 $6.53B $8.28B 0.79
2018-09-30 $5.96B $7.71B 0.77
2018-06-30 $6.62B $7.87B 0.84
2018-03-31 $5.62B $7.29B 0.77
2017-12-31 $6.79B $7.15B 0.95
2017-09-30 $6.62B $7.13B 0.93
2017-06-30 $6.50B $6.48B 1.00
2017-03-31 $5.82B $7.01B 0.83
2016-12-31 $6.75B $7.05B 0.96
2016-09-30 $5.60B $6.24B 0.90
2016-06-30 $5.92B $6.31B 0.94
2016-03-31 $4.94B $6.08B 0.81
2015-12-31 $6.31B $6.08B 1.04
2015-09-30 $5.77B $5.74B 1.01
2015-06-30 $5.12B $5.72B 0.89
2015-03-31 $4.73B $6.37B 0.74
2014-12-31 $6.23B $6.01B 1.04
2014-09-30 $5.32B $5.35B 1.00
2014-06-30 $4.32B $4.37B 0.99
2014-03-31 $4.45B $4.85B 0.92
2013-12-31 $5.79B $4.31B 1.34
2013-09-30 $5.61B $4.56B 1.23
2013-06-30 $4.71B $4.45B 1.06
2013-03-31 $4.64B $4.54B 1.02
2012-12-31 $5.29B $3.74B 1.42
2012-09-30 $5.29B $4.41B 1.20
2012-06-30 $4.58B $4.12B 1.11
2012-03-31 $4.73B $3.88B 1.22
2011-12-31 $5.64B $3.88B 1.45
2011-09-30 $5.65B $3.87B 1.46
2011-06-30 $5.57B $3.59B 1.55
2011-03-31 $4.86B $3.35B 1.45
2010-12-31 $4.92B $3.29B 1.49
2010-09-30 $4.18B $2.93B 1.43
2010-06-30 $4.06B $3.13B 1.30
2010-03-31 $3.93B $2.89B 1.36
2009-12-31 $4.24B $2.51B 1.69
2009-09-30 $4.08B $2.48B 1.64
2009-06-30 $3.63B $2.28B 1.59
2009-03-31 $3.28B $2.48B 1.33
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $215.616B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novartis AG (NVS) Switzerland $165.082B 12.17